3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
16
Carcinoma, Non-Small-Cell Lung
8
Urinary Bladder Neoplasms
4
Liver Neoplasms
4
Small Cell Lung Carcinoma
3
Lung Neoplasms
3
Colorectal Neoplasms
2
Biliary Tract Neoplasms
2
Urothelial Cancer
1
Unresectable Hepatocellular Carcinoma
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Malignancies
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Hypertension, Portal
1
Hepato Cellular Carcinoma
1
Hematologic Neoplasms
1
Fibrosis
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma
1
Interventions
pembrolizumab
26
Paclitaxel
25
Carboplatin
19
Bevacizumab
13
Specimen Handling
11
Magnetic Resonance Spectroscopy
9
Doxorubicin
8
Cisplatin
8
Taxes
7
Biopsy
7
olaparib
6
lenvatinib
6
Fulvestrant
6
durvalumab
5
dostarlimab
5
Nivolumab
5
Megestrol Acetate
5
Letrozole
5
Gemcitabine
5
Docetaxel
5
trastuzumab deruxtecan
4
Trastuzumab
4
Tirzepatide
4
Progestins
4
Medroxyprogesterone Acetate
4
Fluorouracil
4
palbociclib
3
ipatasertib
3
atezolizumab
3
abemaciclib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
tremelimumab
×
90 days
×
Clear all
NCT06680739
2026-06-01
SERPENTINE
Vall d'Hebron Institute of Oncology
Phase 2
Recruiting
60 enrolled